NJ Stock: What to Know Before the Bell on November 10, 2025 (Fresh FDA Wins, Dividend Date, and Legal Overhang)
Johnson & Johnson reported Q3 sales up 6.8% to $24.0 billion and raised its 2025 sales outlook. The FDA approved Caplyta for depression adjunct use and Darzalex Faspro for high-risk smoldering myeloma. A $1.30 dividend is set for December 9. Litigation risk remains after a near-$1 billion talc verdict and new UK lawsuits.